The mechanism involving combined BRAF inhibition and WNT/β‐catenin activation involved AXIN1 degradation and GSK3β inhibition, while hyperactivation of the MAPK/ERK pathway stabilized AXIN1 and consequently inhibited WNT signaling in melanoma [365]. The gene discussed is BRAF; the disease is melanoma.